Toronto, ON June 17, 2003 A collaboration agreement between Arius Research and Protein Design Labs has been extended and expanded. Under the terms of the revised, three-year agreement, Arius will be paid a technology access fee and will use these funds to support its research efforts into new, anti-cancer antibodies. PDL will continue pre-clinical development of the antibody candidates and will have the option to license a number of the antibodies to add to their clinical development pipeline.
Arius Research says it is poised to enter clinical trials with its lead anti- cancer antibody in 2004. It also has eight antibodies that have shown positive effects in animal models, two of which will be presented at the American Association for Cancer Research in July.